AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02338778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
Study NCT00591188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine, interferon-alpha
Description: Patients who meet inclusion/exclusion criteria will receive combination of study drugs.
Study NCT02633878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine plus Oral Micronized Progesterone
Description: Chinese Herbal Medicine (1 pack 2 times a day) + Oral Micronized Progesterone (100 mg three times a day)
Study NCT02633878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine plus Oral Micronized Progesterone Placebo
Description: Chinese Herbal Medicine (1 pack 2 times a day) + Oral Micronized Progesterone Placebo (100 mg three times a day)
Study NCT02633878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine Placebo plus Oral Micronized Progesterone
Description: Chinese Herbal Medicine Placebo (1 pack 2 times a day) + Oral Micronized Progesterone (100 mg three times a day)
Study NCT02633878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese Herbal Medicine Placebo plus Oral Micronized Progesterone Placebo
Description: Chinese Herbal Medicine Placebo (1 pack 2 times a day) + Oral Micronized Progesterone Placebo (100 mg three times a day)
Study NCT03761173 — intervention group
Intervention type: DEVICE
Intervention: FlowTriever System
Description: Thrombectomy
Study NCT03761173 — intervention group
Intervention type: DRUG
Intervention: Anticoagulation Agents
Description: Anticoagulation medication
Study NCT03565445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenously (IV)
Study NCT03565445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Intravenously (IV)
Study NCT03565445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Intravenously (IV)
Study NCT03480776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: 81 mg PO daily or 325 mg PO daily
Study NCT03480776 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: One tablet PO daily
Study NCT02504658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle text messages
Description: Throughout the course of the four-week study, the experimental participants will receive one text message each morning related to general nutrition and exercise goals, and an additional goal status update message on Monday, Wednesday, and Friday evenings. The goal status update message will ask the participants about the status of attaining their nutrition or physical activity goals. Participants may log their progress toward attaining their goals by using the mobile health dashboard feature on BodiMojo.com from a computer or a web-enabled smartphone to indicate their goal status (still working on it or completed it). Participants will be encouraged, via the text messages, to look at information on the BodiMojo program found on the Bodimojo.com website.
Study NCT02504658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Group
Description: Once participants randomized to the control group have completed the baseline assessment, they will be asked to write down two health goals with the RA. The same goals will be suggested for this group as for the Intervention group (see Appendix). They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over.
Study NCT02465593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP503
Description: The volume of PEP503 to be administered is based on the baseline tumor volume of each patient. There will be 4 dose levels in Phase Ib.
Study NCT02465593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 225 mg/m2 a day, 5 days/week for 5 weeks during radiotherapy period
Study NCT02465593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 825 mg/m2 BID 5 days/week for 5 weeks during the radiotherapy period
Study NCT02465593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical resection
Description: Approximately 8 weeks after the completion of chemoradiotherapy, surgical resection of the tumor (total mesorectal excision, TME) will be performed once the tumor become resectable.
Study NCT02465593 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Intensity-modulated radiation therapy (IMRT) or intensity modulated arc therapy (IMAT) of 5,000 cGy in 25 fractions (200 cGy/fraction, 5 times/week) to gross tumor and involved nodes and 4,500 cGy in 25 fractions (180 cGy/fraction, 5 times/week) to pelvis, starting at 24 hours after PEP503 injection.
Study NCT03009526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Description: 500 mg sulfadoxine and 25 mg pyrimethamine
Study NCT03009526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Description: 40 mg dihydroartemisinin and 320 mg piperaquine
Study NCT02718053 — intervention group
Intervention type: OTHER
Intervention: L-stiff
Description: spasticity measurement with Lokomat
Study NCT02718053 — intervention group
Intervention type: OTHER
Intervention: Ashworth
Description: spasticity measurement with Ashworth scale
Study NCT01343147 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Microwave diathermy
Description: Deep tissue heating via microwave diathermy
Study NCT01343147 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Superficial hyperthermia
Description: Superficial heating via hot pack application
Study NCT02395588 — intervention group
Intervention type: OTHER
Intervention: Guideline based care
Description: Patient education using guideline based teaching guides
Study NCT04011995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent caloric restriction
Description: The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted.
Study NCT04011995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet
Description: During the 14-day intervention period, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted.
Study NCT04011995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education on reducing the cardiometabolic risk
Description: Health education is conducted once a week during 14-day dietary intervention for all subjects. Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
Study NCT04011995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education on reducing the cardiometabolic risk
Description: Health education is conducted once a week during 14-day dietary intervention for all subjects. Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
Study NCT03043950 — intervention group
Intervention type: DRUG
Intervention: Panitumumab
Description: Patients will be scheduled to receive first line therapy with the combination of Panitumumab (6 mg / kg i.v, given once every two weeks) and FOLFIRI or FOLFOX, according to current SmPC.
Study NCT03266003 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electronic DOT
Description: Electronic DOT is the use of electronic communication methods to observe patients swallow anti-TB drugs and monitor for medication side effects. This study will use two variations of electronic communication methods, referred to as electronic directly observed therapy or eDOT. This includes: (1) eDOT conducted live in which TB program staff interact with patients via a computer or phone application as they ingest their medication (eDOT-live), and (2) eDOT conducted using time stamped, recorded videos in which TB program staff log into an electronic system and review videos recorded by patients in order to verify that patients ingested their medication doses as scheduled (eDOT-recorded).
Study NCT03266003 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: In-person DOT
Description: A trained person is in the physical presence of patients as anti-TB drugs are ingested.
Study NCT03425045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Patients randomised in Arm 1 will receive stimulation of the dorsolateral prefrontal cortex (frequency 25 Hz; 300 pulses; 80% resting motor threshold=RMT) and primary auditory cortex on both sides (1 Hz; 1000 pulses; 110% RMT) will be stimulated in patients in rTMS stimulation group for 5 consecutive days. No medication therapy will be provided for patients in this arm.
Study NCT03425045 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation will be performed in patients randomised in Arm 2 of the study for 5 consecutive days. No medication therapy will be provided for patients in this arm.
Study NCT03425045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Biloba Extract
Description: Patients randomised in Arm 3 of the study will receive medication therapy with Ginkgo biloba extract EGb 761 once a day for 6 months.
Study NCT01745380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: The study drug is regional anesthetic delivered intranasally on the same side as the operative tooth
Study NCT01745380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo spray was identical in appearance to and was administered in the same volume and manner as the active ingredient.
Study NCT01914315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: Patients will participate in a 6-month cardiac rehabilitation program, consisting of structured, 60-minutes, bi-weekly exercise training sessions according to a predefined protocol. Institutional activity will be complemented by 120 minutes weekly home exercise prescribed by specialist in cardiac rehabilitation. Exercise prescription will be based on a symptom limited exercise test when clinically feasible and according with the patients' functional capacity, medical history and physiological values obtained prior to exercise. Target heart rate will be set initial as 50-60% of heart rate reserve and gradually increased up to 80% of HRR. Aerobic exercise will be complemented by resistance training of low intensity.
Study NCT01914315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internal Medicine
Description: Following discharge, patients will return to the IM outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated. Target values for blood pressure and glucose control will be in accordance with current guidelines and special emphasis given to management of fluid retention.
Study NCT02056730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium sensing receptor agonist
Description: For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).
Study NCT02847533 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sample
Description: blood sample for concentration levels of inflammatory markers
Study NCT02847533 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychometric scales
Description: Mini international interview MADRS, C-SSRS, QIDS-SR, BIS-10, BDHI, BART, ERD
Study NCT03337087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03337087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT03337087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Given PO
Study NCT02056210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mozobil
Description: Subcutaneous injection of 0.24 mg/kg Mozobil once at 8:30am
Study NCT03224767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO
Study NCT03224767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO
Study NCT03224767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03224767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04147884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Millipede Transcatheter Annuloplasty Ring System (Millipede System)
Description: The Millipede Transcatheter Annuloplasty Ring System is a repair device used for treating mitral valve regurgitation (MR). The system consists of several components: a transcatheter annuloplasty ring (implant) which remains in the body and a delivery system and intracardiac echocardiography catheter (imaging device) used to deliver the implant to the mitral valve.
Study NCT02412137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseled cohort
Description: This group will be counseled after brace temperature/date/time data is logged at each visit.
Study NCT02412137 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Counseled cohort
Description: This group will be counseled after brace temperature/date/time data is logged at each visit.
Study NCT04837625 — intervention group
Intervention type: OTHER
Intervention: no interventions
Description: no interventions
Study NCT01261520 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Culturally-tailored video
Description: A 18 minute DVD made in Chinese language (i.e. Mandarin and Cantonese)
Study NCT03763331 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control/Sham Treatment
Description: Thermoneutral water will be circulated through water-circulating trousers to maintain skin temperature at baselines levels daily for 90 minutes for 8 weeks.
Study NCT03763331 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heat Therapy
Description: Water at 110 degrees F will be circulated through water-circulating trousers daily for 90 minutes for 8 weeks.
Study NCT03058536 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arabin Pessary
Description: The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner.
Study NCT03058536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Progesterone
Description: Treatment with 400 mg micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
Study NCT03058536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arabin Pessary and Progesterone
Description: Arabin Pessary and Progesterone The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner. Treatment with 400 mg Micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
Study NCT01050231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional/ Multi-joints activities
Description: Subjects participated in 4 weeks of robotic training with the device: BONES (Biomimetic Orthosis Neurorehabilitation for Elbow and Shoulder), 3 days per week, 1 hour per day with the robotic exercise program focusing on functional tasks such as cleaning the windows, driving a steering wheel, grocery shopping, etc.
Study NCT01050231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional/ Multi-joints activities
Description: Subjects participated in 4 weeks of robotic training with the device: BONES (Biomimetic Orthosis Neurorehabilitation for Elbow and Shoulder), 3 days per week, 1 hour per day with the robotic exercise program focusing on functional tasks such as cleaning the windows, driving a steering wheel, grocery shopping, etc.
Study NCT01050231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individual Joint Training
Description: Subjects participated in 4 weeks of training with the robotic device BONES, 3 days per week, 1 hour per day with a robot-assisted exercise program. The robotic exoskeleton assists in arm and hand movements focusing on one joint at a time.
Study NCT01050231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Individual Joint Training
Description: Subjects participated in 4 weeks of training with the robotic device BONES, 3 days per week, 1 hour per day with a robot-assisted exercise program. The robotic exoskeleton assists in arm and hand movements focusing on one joint at a time.
Study NCT03654534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NutrenOpimum
Description: NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
Study NCT01443546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG
Description: hCG Trigger
Study NCT01443546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron Trigger
Description: leuprolide acetate 2 mg SQ
Study NCT04356573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green Hayward Kiwifruit first, then Gold Kiwifruit
Description: Subjects ate 2 peeled green kiwifruit with their midday meal for 2 weeks prior to testing.
Study NCT04356573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green Hayward Kiwifruit first, then Gold Kiwifruit
Description: Subjects ate 2 peeled green kiwifruit with their midday meal for 2 weeks prior to testing.
Study NCT04356573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gold Kiwifruit First, then Green Hayward Kiwifruit
Description: Subjects ate 2 peeled gold kiwifruit with their midday meal for 2 weeks prior to testing.
Study NCT04356573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gold Kiwifruit First, then Green Hayward Kiwifruit
Description: Subjects ate 2 peeled gold kiwifruit with their midday meal for 2 weeks prior to testing.
Study NCT00428194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 40 mg/m\^2 every 7 days during radiation
Study NCT00428194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 40 mg/m\^2 every 7 days during radiation
Study NCT00428194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Erlotinib escalating dose per schedule - 100, 125 and 150 mg/m\^2 by mouth once a day beginning day 1.
Study NCT00428194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: Erlotinib escalating dose per schedule - 100, 125 and 150 mg/m\^2 by mouth once a day beginning day 1.
Study NCT00428194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: standard (fixed) doses of pelvic irradiation (as determined by their radiation oncologist)
Study NCT00428194 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: standard (fixed) doses of pelvic irradiation (as determined by their radiation oncologist)
Study NCT02002117 — intervention group
Intervention type: OTHER
Intervention: DNA mass
Description: DNA mass spectrometry
Study NCT02273206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Care Management for Depression and Cancer Screening
Study NCT02273206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevention Care Management for Cancer Screening
Study NCT02273206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Care Management for Cancer Screening
Study NCT05398575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Participants listen to music during physiotherapy rehabilitation (tailored or radio music)
Study NCT05398575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Participants listen to music during physiotherapy rehabilitation (tailored or radio music)